| [1] |
|
| [2] |
Teng M L, Ng C H, Huang D Q, et al. Global incidence and prevalence of nonalcoholic fatty liver disease[J]. Clin Mol Hepatol, 2023, 29(Suppl): S32-S42. DOI: 10.3350/cmh.2022.0365.
|
| [3] |
Zhao Y C, Zhao G J, Chen Z, et al. Nonalcoholic fatty liver disease: an emerging driver of hypertension[J]. Hypertension, 2020, 75(2): 275-284. DOI: 10.1161/HYPERTENSIONAHA.119.13419.
|
| [4] |
Lonardo A, Nascimbeni F, Mantovani A, et al. Hypertension, diabetes, atherosclerosis and NASH: cause or consequence?[J]. J Hepatol, 2018, 68(2): 335-352. DOI: 10.1016/j.jhep.2017.09.021.
|
| [5] |
Soleimani M, Barone S, Luo H, et al. Pathogenesis of hypertension in metabolic syndrome: the role of fructose and salt[J]. Int J Mol Sci, 2023, 24(5): 4294. DOI: 10.3390/ijms24054294.
|
| [6] |
Ciardullo S, Grassi G, Mancia G, et al. Nonalcoholic fatty liver disease and risk of incident hypertension: a systematic review and meta-analysis[J]. Eur J Gastroenterol Hepatol, 2022, 34(4): 365-371. DOI: 10.1097/MEG.0000000000002299.
|
| [7] |
Guo T, Zhou Y, Yang G F, et al. Association between cardiometabolic index and hypertension among US adults from NHANES 1999-2020[J]. Sci Rep, 2025, 15(1): 4007. DOI: 10.1038/s41598-025-87029-0.
|
| [8] |
Liu X, Wu Q, Yan G, et al. Cardiometabolic index: a new tool for screening the metabolically obese normal weight phenotype[J]. J Endocrinol Investig, 2021, 44(6): 1253-1261. DOI: 10.1007/s40618-020-01417-z.
|
| [9] |
|
| [10] |
|
| [11] |
郭凯明, 伊娜, 赵振平, 等. 中国成人BMI和腹型肥胖与T2DM发病关系的前瞻性研究[J]. 中华疾病控制杂志, 2023, 27(11): 1342-1349.
|
| [12] |
Lou T W, Yang R X, Fan J G. The global burden of fatty liver disease: the major impact of China[J]. Hepatobiliary Surg Nutr, 2024, 13(1): 119-123. DOI: 10.21037/hbsn-23-556.
|
| [13] |
Shih C I, Wu K T, Hsieh M H, et al. Severity of fatty liver is highly correlated with the risk of hypertension and diabetes: a cross-sectional and longitudinal cohort study[J]. Hepatol Int, 2024, 18(1): 138-154. DOI: 10.1007/s12072-023-10576-z.
|
| [14] |
Mori K, Tanaka M, Hosaka I, et al. Metabolic dysfunction-associated fatty liver disease is associated with an increase in systolic blood pressure over time: linear mixed-effects model analyses[J]. Hypertens Res, 2023, 46(5): 1110-1121. DOI: 10.1038/s41440-023-01179-0.
|
| [15] |
Cattazzo F, Lombardi R, Mantovani A, et al. Subclinical and clinical atherosclerosis in non-alcoholic fatty liver disease is associated with the presence of hypertension[J]. Nutr Metab Cardiovasc Dis, 2022, 32(12): 2839-2847. DOI: 10.1016/j.numecd.2022.08.005.
|
| [16] |
Wakabayashi I, Daimon T. The "cardiometabolic index" as a new marker determined by adiposity and blood lipids for discrimination of diabetes mellitus[J]. Clin Chim Acta, 2015, 438: 274-278. DOI: 10.1016/j.cca.2014.08.042.
|
| [17] |
Zhou H T, Mao Y, Ye M Y, et al. Exploring the nonlinear association between cardiometabolic index and hypertension in U.S. Adults: an NHANES-based study[J]. BMC Public Health, 2025, 25(1): 1092. DOI: 10.1186/s12889-025-22231-3.
|
| [18] |
|
| [19] |
Acosta-García E, Concepción-Páez M. Cardiometabolic index as a predictor of cardiovascular risk factors in adolescents[J]. Rev Salud Publica (Bogota), 2018, 20(3): 340-345. DOI: 10.15446/rsap.V20n3.61259.
|
| [20] |
Li Y, Zeng L. Comparison of seven anthropometric indexes to predict hypertension plus hyperuricemia among U.S. adults[J]. Front Endocrinol, 2024, 15: 1301543. DOI: 10.3389/fendo.2024.1301543.
|
| [21] |
Heymsfield S B, Wadden T A. Mechanisms, pathophysiology, and management of obesity[J]. N Engl J Med, 2017, 376(3): 254-266. DOI: 10.1056/NEJMra1514009.
|
| [22] |
Leggio M, Lombardi M, Caldarone E, et al. The relationship between obesity and hypertension: an updated comprehensive overview on vicious twins[J]. Hypertens Res, 2017, 40(12): 947-963. DOI: 10.1038/hr.2017.75.
|
| [23] |
Yang Q, Vijayakumar A, Kahn B B. Metabolites as regulators of insulin sensitivity and metabolism[J]. Nat Rev Mol Cell Biol, 2018, 19(10): 654-672. DOI: 10.1038/s41580-018-0044-8.
|
| [24] |
Haukeland J W, Damås J K, Konopski Z, et al. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2[J]. J Hepatol, 2006, 44(6): 1167-1174. DOI: 10.1016/j.jhep.2006.02.011.
|
| [25] |
Casino P R, Kilcoyne C M, Quyyumi A A, et al. The role of nitric oxide in endothelium-dependent vasodilation of hypercholesterolemic patients[J]. Circulation, 1993, 88(6): 2541-2547. DOI: 10.1161/01.cir.88.6.2541.
|
| [26] |
Gu D X, Lu Y Y, Xu B Q, et al. Sex-specific contribution of cardiometabolic index in predicting metabolic dysfunction-associated fatty liver disease: insights from a general population[J]. Diabetes, Metabolic Syndrome and Obesity, 2023, 16: 3871-3883. DOI: 10.2147/DMSO.S437413.
|
| [27] |
He L Y, Sun L, Pan H H, et al. Association between cardiometabolic index and blood pressure: a cross-sectional analysis of the NHANES 2015-2018 data[J]. Rev Cardiovasc Med, 2025, 26(5): 37359. DOI: 10.31083/RCM37359.
|
| [28] |
Song J M, Li Y M, Zhu J X, et al. Non-linear associations of cardiometabolic index with insulin resistance, impaired fasting glucose, and type 2 diabetes among US adults: a cross-sectional study[J]. Front Endocrinol, 2024, 15: 1341828. DOI: 10.3389/fendo.2024.1341828.
|